0001633070-21-000040.txt : 20210729
0001633070-21-000040.hdr.sgml : 20210729
20210729075830
ACCESSION NUMBER: 0001633070-21-000040
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 14
CONFORMED PERIOD OF REPORT: 20210729
ITEM INFORMATION: Results of Operations and Financial Condition
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20210729
DATE AS OF CHANGE: 20210729
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axcella Health Inc.
CENTRAL INDEX KEY: 0001633070
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38901
FILM NUMBER: 211124872
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: THIRD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-868-0949
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: THIRD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Pronutria Biosciences, Inc.
DATE OF NAME CHANGE: 20150206
8-K
1
axla-20210729.htm
8-K
axla-20210729
0001633070FALSE840 Memorial DriveCambridgeMassachusetts00016330702021-07-292021-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):July 29, 2021
_____________________
AXCELLA HEALTH INC.
(Exact name of registrant as specified in its charter)
________________________
Delaware
001-38901
26-3321056
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
840 Memorial Drive
Cambridge, Massachusetts
02139
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (857) 320-2200
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value
AXLA
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02.Results of Operations and Financial Condition.
On July 29, 2021, Axcella Health Inc. announced its financial results for the second quarter ended June 30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AXCELLA HEALTH INC.
Date: July 29, 2021
By:
/s/ William R. Hinshaw, Jr.
William R. Hinshaw, Jr.
President, Chief Executive Officer and Director
EX-99.1
2
ex9912021q2.htm
EX-99.1
Document
Exhibit 99.1
Axcella Reports Second Quarter Financial Results and Provides Business Update
•Initiated EMMPOWER Phase 2 clinical trial of AXA1665 for the reduction in risk of recurrent OHE
•Initiated EMMPACT Phase 2b clinical trial of AXA1125 for the treatment of NASH
•Presented data at key medical congresses
•Enhanced management team with the addition of Chief People Officer
•Company to host conference call at 8:30 a.m. ET today
Cambridge, Mass., July 29, 2021 – Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
“Thanks to solid execution on the part of our team, Axcella has rapidly advanced the development of its multi-targeted EMM compositions in order to address significant unmet needs for patients with complex diseases,” said Bill Hinshaw, President and Chief Executive Officer of Axcella. “Our progress continued in the second quarter as we initiated the EMMPOWER Phase 2 clinical trial of AXA1665 in overt hepatic encephalopathy (OHE) as well as the EMMPACT Phase 2b clinical trial of AXA1125 in nonalcoholic steatohepatitis (NASH). With a high level of interest and engagement from the medical community and many clinical sites already activated for each of these global trials, I am pleased to report that we are off to a strong start. As we enter the second half of 2021, maximizing clinical trial enrollment and expanding Axcella’s pipeline are our primary areas of focus.”
Recent Accomplishments
AXA1665 for the Reduction in Risk of Recurrent OHE
•Initiated EMMPOWER Clinical Trial: Axcella recently initiated its EMMPOWER Phase 2 clinical trial. This global 24-week, randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of AXA1665 in approximately 150 patients who have experienced at least one prior OHE event and have neurocognitive dysfunction at screening.
•Presented Orally at DDW 2021: Data from Axcella’s AXA1665-002 clinical study were highlighted in an oral presentation at the Digestive Disease Week (DDW) 2021 Annual Meeting by Dr. Arun Sanyal, Professor in the Virginia Commonwealth University (VCU) Department of Internal Medicine and Education Core Director in the VCU Center for Clinical and Translational Research.
AXA1125 for the Treatment of NASH
•Initiated EMMPACT Clinical Trial: In April, the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for AXA1125. Shortly thereafter, Axcella initiated its EMMPACT Phase 2b clinical trial. This global 48-week, randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of AXA1125 in approximately 270 patients with biopsy-confirmed F2/F3 NASH.
•Published Findings in Nature’s Scientific Reports: Nature’s Scientific Reports published findings from a systematic evaluation of AXA1125’s EMM constituents across multiple primary human cell model systems demonstrating that they consistently and simultaneously impacted NASH-relevant metabolic, inflammatory and fibrotic processes.
•Presented at ADA 81st Scientific Sessions: Clinical and nonclinical data regarding the effects from AXA1125 and its EMM constituents on insulin sensitivity were included in a poster presentation at the American Diabetes Association (ADA) 81st Scientific Sessions.
Management Team
•Added Virginia Dean as Chief People Officer: In June 2021, Axcella appointed Virginia Dean as the company’s Senior Vice President and Chief People Officer. In this role, Ms. Dean is leading the company’s organizational and cultural development initiatives with responsibility for all human resources functions. She previously headed up ClearSight Leadership, a consulting firm specializing in HR services, and led the human resources functions for several high-growth companies, including TESARO, Inc. and ARIAD Pharmaceuticals.
Financial Results
Cash Position: As of June 30, 2021, cash, cash equivalents, and marketable securities totaled $78.9 million, compared to $107.3 million at December 31, 2020. Axcella continues to expect that its existing cash balance will be sufficient to meet the company’s operating needs into the third quarter of 2022.
R&D Expenses: Research and development expenses for the quarter and six months ended June 30, 2021 were $10.3 million and $20.5 million, respectively. Research and development expenses for the same periods ended June 30, 2020 were $8.6 million and $18.9 million. These increases are primarily the result of work related to the initiations of the company’s EMMPOWER and EMMPACT clinical trials.
G&A Expenses: General and administrative expenses for the quarter and six months ended June 30, 2021 were $4.9 million and $9.2 million, respectively. General and administrative expenses for the same periods ended June 30, 2020 were $4.6 million and $8.7 million. These increases are primarily the result of greater non-cash stock-based compensation expenses and benefit-related costs.
Net Loss: Net loss for the quarter and six months ended June 30, 2021 was $15.9 million, or $0.42 per basic and diluted share, and $31.1 million, or $0.83 per basic and diluted share, respectively. This compares with a net loss of $13.9 million, or $0.48 per basic and diluted share, and $28.9 million, or $1.10 per basic and diluted share, for the quarter and six months ended June 30, 2020.
Conference Call Reminder
Axcella will host a conference call today at 8:30 a.m. ET to discuss the company’s financial results and other recent business updates. The conference call webcast will be accessible in the Investors & News section on the company’s website at www.axcellahealth.com. To access the call via telephone, please dial (844) 808-7139 (U.S. toll free) or (412) 902-0127 (international) five minutes prior to the start time. For those unable to listen in live, a webcast archive will be available on the company’s website for 90 days following the call.
About Endogenous Metabolic Modulators (EMMs)
EMMs are a broad family of naturally occurring molecules, including amino acids, that regulate human metabolism. Axcella is developing a range of novel product candidates that are comprised of multiple EMMs engineered in distinct combinations and ratios to simultaneously impact multiple metabolic pathways to modify the underlying causes of various complex diseases and improve health.
About Axcella’s Clinical Development
Each of the clinical investigations that the company has completed to date have been conducted as non-investigational new drug application (IND) “clinical studies” under U.S. Food and Drug Administration regulations and guidance supporting research with food. These studies evaluate product candidates for safety, tolerability and effects on the normal structures and functions in humans, including in individuals with disease. They are not designed or intended to evaluate a product candidate’s ability to diagnose, cure, mitigate, treat or prevent a disease. If and when Axcella decides to develop a product candidate as a potential therapeutic, as is the case with AXA1665 and AXA1125, the company will seek an IND to enable the initiation of “clinical trials.”
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the characteristics, competitive position and development potential of AXA1665, AXA1125 and potential future EMM compositions, the company’s ability to enroll its EMMPOWER and EMMPACT clinical trials in a timely manner, its ability to expand the company’s pipeline, and the company’s expected cash runway. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the potential impact of COVID-19 on the company’s ability to conduct and complete its ongoing or planned clinical studies and clinical trials in a timely manner or at all due to patient or principal investigator recruitment or availability challenges, clinical trial site shutdowns or other interruptions and potential limitations on the quality, completeness and interpretability of data the company is able to collect in its clinical trials of AXA1665 and AXA1125, other potential impacts of COVID-19 on the company’s business and financial results, including with respect to its ability to raise additional capital and operational disruptions or delays, changes in law, regulations, or interpretations and enforcement of regulatory guidance, whether data readouts support the company’s clinical trial plans and timing, clinical trial design and target indications for AXA1665 and AXA1125, the clinical development and safety profile of AXA1665 and AXA1125 and their therapeutic potential, whether and when, if at all, the company’s product candidates will receive approval from the FDA or other comparable regulatory authorities, potential competition from other biopharma companies in the company’s target indications, and other risks identified in the company’s SEC filings, including Axcella’s Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Axcella disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The company explicitly disclaims any obligation to update any forward-looking statements.
Axcella Health Inc.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
June 30,
December 31,
2021
2020
Assets:
Cash and cash equivalents
$
33,940
$
71,590
Marketable securities
45,003
35,739
Other assets
2,541
2,263
Total assets
$
81,484
$
109,592
Liabilities and stockholders' equity:
Liabilities
$
33,397
$
34,211
Stockholders' equity
48,087
75,381
Total liabilities and stockholders' equity
$
81,484
$
109,592
Axcella Health Inc.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
Three Months Ended June 30,
Six Months Ended June 30,
2021
2020
2021
2020
Operating expenses:
Research and development
$
10,298
$
8,565
$
20,538
$
18,900
General and administrative
4,946
4,619
9,202
8,744
Total operating expenses
15,244
13,184
29,740
27,644
Loss from operations
(15,244)
(13,184)
(29,740)
(27,644)
Other income (expense):
Interest income (expense) and other income (expense), net
(691)
(708)
(1,384)
(1,257)
Total other income (expense), net
(691)
(708)
(1,384)
(1,257)
Net loss
$
(15,935)
$
(13,892)
$
(31,124)
$
(28,901)
Net loss per share, basic and diluted
$
(0.42)
$
(0.48)
$
(0.83)
$
(1.10)
Weighted average common shares outstanding, basic and diluted
37,732,196
29,202,367
37,692,398
26,195,591
Company Contact
Jason Fredette
jfredette@axcellahealth.com
(857) 320-2236
EX-101.SCH
3
axla-20210729.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
0001001 - Document - Coverlink:presentationLinklink:calculationLinklink:definitionLinkEX-101.LAB
4
axla-20210729_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Pre-commencement Tender OfferPre-commencement Tender OfferAmendment FlagAmendment FlagEntity Address, State or ProvinceEntity Address, State or ProvinceEntity Ex Transition PeriodEntity Ex Transition PeriodEntity Tax Identification NumberEntity Tax Identification NumberTitle of 12(b) SecurityTitle of 12(b) SecurityEntity File NumberEntity File NumberWritten CommunicationsWritten CommunicationsPre-commencement Issuer Tender OfferPre-commencement Issuer Tender OfferEntity Emerging Growth CompanyEntity Emerging Growth CompanyTrading SymbolTrading SymbolDocument Period End DateDocument Period End DateSoliciting MaterialSoliciting MaterialDocument TypeDocument TypeCity Area CodeCity Area CodeEntity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeEntity Address, Address Line OneEntity Address, Address Line OneEntity Registrant NameEntity Registrant NameLocal Phone NumberLocal Phone NumberEntity Address, City or TownEntity Address, City or TownCover [Abstract]Entity Address, Postal Zip CodeEntity Address, Postal Zip CodeEntity Central Index KeyEntity Central Index KeySecurity Exchange NameSecurity Exchange NameEX-101.PRE
5
axla-20210729_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
GRAPHIC
6
image_0a.jpg
GRAPHIC
begin 644 image_0a.jpg
MB5!.1PT*&@H -24A$4@ 6P !A" 8 #R=IO3 CJ$E$051XVNV=
M"7P;Q;G %0H$2DH.R&6O%)JC0#A+: N\O&<:'U(>/(Y"H-#RVD.K<-Q#H)SV3E])'9\2;NSNUIIM?MFI6BS
M6AU>2:O#]GR_W_<3.-K9F='.?[_Y9N;[=#HD"0O/\T:?SU>!>@()$B1I%8[C
MMD$ C4 ]H0K4HR&H]PA0X.KUW0$XS?E![@,"L?9BA
MR\8(E&4, C82)$C2*X-?W.0:\!'6"-A(D"#)&+"'OK19$/6AQ;6LQ\-Y9.">V1_[!+:['"HO]H&W]7N6FG\#
M%P0U C82)$BR MA!75O5Y H"R^\*X/D)_:$O8#NO@>WF_"\K+\O3*^]@E*!&
MP$:"!$E6 5O4*Z=OXPZ=<)$R:[L&?ES41T$]3-SU$6RKNWHV RQC^&BP1L!&
M@@1)5@$[J'?@-C?->#B9M5T,/P;TA;;#=IP'03U;6G3M.,)1Y6,]L4"-@(T$
M"9*L!790YV]HD"]*DA#<_];+K>JIL!V4_R7$L0+]T0-N-:!&P$:"!$G6 UO4
M82]MXH^<)E@9N.LA^(;W,JOZW1_$!6H$;"1(DI>\"N&B?"MY
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MH1OX_?G!2(*^KJ,K^O:S
MWQ-X+RTPGSSLS@2H$;"1($' [G? %G7LZQ6^HZ=)^6Z2@\I%29[G+S[[]X#[
MHWHNZ"GT*0(V$B0(V C8*=)[9]L\%..1QR:9*89PA5IZ[O#+/@^8\S-?ID&-
M@(T$"0)VOP9V<#?)_&\.RT.X!C*4^[P"_?Y4;[: &@$;"1($['X/;%&O?:O2
MVWCF7%P2OPMDSP<4*!O+(6 C08* C8"=)YV@.R2,I%Q_'\]__W$Q_7"?/^V2 M2G*=1SW4DML\
M_178E%E_,VW!ID/]!I@-C6KJ25H,+93%\"W L6)XS4U:UJ?0WOU3N194M>=D
MZCE6UF6*C1RI1;E%.\A"HYV:8;*#328;V:@$1"0UV%=W 56>>Q_\X6DMZTZ:]+;03)WY=
MY1RG2W%.U%NLC1<7U5#/:EW_(@?X2.R?_@!LH5AW'H,/'T=;]$U:LX/ <^^K
M*]9=V&N O<;:+(5A]7@XSW\LJ&'E_QX)V/Y#-_,<;N:L-X 9FRM,TR4XTUU!*M^^(.FVL"M*2MJ:Z_T0:.%CJ(>_LJL,4Q 2P8
MD]JQ9X &I^'KKM*A@[,6V%/+K=+1=#%3S;+-1[LC?2\:L*5#-UL;N[C@+A(6
M"-3"27Q? '8Q?*L3%L.*^.N",:#, "2U&.*._4V5&9Y.I,ZBZ\%H(WVA@X^:
MF0Y83UPM7!AF!=K(FKC 82-_GQBT2&JJC022)FQU@Q>3M;@+:KL&FZSJW#4A
M;1!?MDFTP>@@N0);8KD8LQ'85*GA_@3 RX6,/:AQEU&&K:E_6CV
M"/4MA'0D_7 3T3W^S6U%3,!,E$V^G* Y]Q(X]C#\,':T>.#8]:?Z"X>/"1^ZY1^
M*0Q$#G!CJH$-+;WM80-V]6I5LP71;0"!T]RC&P""V6@EEQ3:P-0":,%"BSZJ
M/UKT]>8YP"CC3G"3R4K<"Z]?#D'D5&%Q-^95".)$-M*NPN%?U=F#3N'Y?C^/>G%M+F[$777C.
MK5VEHPVU3^BBNO^ZB\<,<9ESKH0P-I(6_>)(OV@%N
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MW<3P5+YHQF^H'U@8Q0T#^X]2_P( 'T=M1Q5USK= -*U O7UQ=OX
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M]V^Y*\UY0)FOG=[;XX64_\58TZE/=]W%+9SBGFUE7?Q;%WN1#QN4YE8%
M?-38NDP\ XQYS*_#7:&&(^H6(5_8O"I>0/[7LMT^CY?CS\8 X1=L.DHE _YD
M@1W4.1N.2/N\?50GQ[Q70"2P>P*0%BSEB80[BH==ZK'D_BJ3\ #XF&K%ZC4K
MQ%A8B;X(2=*A[@K1 DY^[_$4*[@I#+A5Y._5^6!#?=YGK<%G=%D@1BNUQ=^6
M:C)?Q0OK[3#+NIJ\-E-UG_1N[05A_6H'5;UMT1%:NG_.Z-@S8X\IV<.78^H.
M7%WRW/KKU !1__)FHZ?B9A_8"/N%6+@5140_XC>6N4Y!7E?J?>,J=MH8= B.9LZG>UNT0@
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M_Q;J$L+:DH!L,@'U!:<+=5\3]1;[T>OT@!!V=O_7U"9PED
MULP2BFSDYZ$[1N@_(& G-\,5M]XF5,C09[^]YIKB;># "2E!N> XU,Y>5;Q=
M&/;*%LUU5D4 V$]^4I>2\L>]42'4'NJ28F][CFVGF5EC6]REHZ[6]7-A2L9<
MH9QQ).S?K!4N*+*2E *VUK@L=3N%18AI,2<^=T/;(,7VN<.]\;<1#R,I]EK_
MD"UU@[_KVZ' ILP(V,F[).,N /+L?&B1E@7AY@*L[TZ+0QCQ>D7*=,ZV$_Y[
M_67U@93>Y_8953Q!L?*DP&O@QX4(V-H VS\P:^G)$4Y!_D'U]0ZJ-?14(.B,
MWS_<-X MGCY4+.[M0\!&P):$Y_G[(<2DA +X5_4\5EPIC)Z^/:4ZK_*D_WY_
M77LPY??2P_;,^.JP'-I>V.X_(6!K VR_2\,.RI2^5Y6ND"\4NTVX29NZ!B-@
M(V C8(>".A>"JR$(L0--+G["/ZH$[*WTZ/P=3?[[/OWYX;3=4]3OFUSRA,
M]L-X!.PQF@R"J3;B5-A.@AA!CXQV^E_#7"%6\N%$[HV C8#=9X$-0;52GOGE
MWQ?M\OUTAE5(IRZL:O;?^]DOZX5TW_OV!;LXCY=C90EOMB%@:^!_W9,L-L@&,FU\R-T -@;C@G94)]I
M*__*L%ZD&MG^PV@&I&-Q;_99U
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MOESE=]I*6[ 7Z'(L3TQ\$-/O_9[N(C$4,X/G
M/LF8#9]246)?R\._7GY;C\58=\5RS>+V1*%^YN#^P2
MV=(L9+(>4]X_P,O<('QM,^T201U4K8!-EHR\/<:TB:%Q_4+-%E!TNO/$J5@\
M4[Z4 2A&'D)CE>LN!.S8P,Y6%7,]]A3G):LRSI09?%'S->)8M;/\TF%:_89T
M&3;+/Z;C'7O*X$@WOE7I;6HCI5TB-
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
